Danielle Boyle: Patient Voices Transform Progress in ITP Research and Care with ISTH
Danielle Boyle, Founder and CEO of ITP Australia and New Zealand, shared International Society on Thrombosis and Haemostasis (ISTH)’s post on LinkedIn, adding:
“I’m incredibly grateful to ISTH for sharing this member spotlight and for recognising the importance of patient voices in ITP research and care.
Founding ITP Australia and New Zealand has shown me, time and time again, that meaningful progress happens when patients, clinicians and researchers work together.
Lived experience brings context, clarity and humanity to the data, and it’s often the missing piece that helps shape research questions, treatment priorities and real ‑ world outcomes.
Hearing the stories, challenges and insights from people living with ITP is what drives this work forward.
Their voices don’t just inform research; they transform it.
Thank you to the International Society on Thrombosis and Haemostasis (ISTH) for highlighting the value of patient ‑ led organisations and for continuing to champion collaboration across the global haematology community.
I’m proud to be a member and part of a network that understands the power of partnership and the impact of listening deeply to the people at the heart of this condition.
- Grateful for the recognition.
- Grateful for the community.
- Grateful for the opportunity to keep pushing for better outcomes.”
International Society on Thrombosis and Haemostasis (ISTH) , shared a post on LinkedIn:
“Meet ISTH member Danielle Boyle, founder and CEO of ITP Australia and New Zealand.
In this video, she highlights the powerful role patient voices play in shaping meaningful research and improving outcomes for the ITP community.
We’re always so inspired to hear about the amazing work that our members are doing across the globe! ”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 13, 2026, 05:36Speaking Up When Women’s Health Concerns Are Dismissed – Haemophilia Foundation Australia
-
Sep 13, 2026, 05:16W. Alberto Sifuentes Giraldo: Dual Targeted Therapy Shows Promise in Refractory Systemic Autoinflammatory Diseases
-
Sep 13, 2026, 04:42Christopher Robinson: Early Pregnancy Oxylipins May Signal Risk of Fetal Growth Restriction
-
Sep 13, 2026, 04:22Gabriela Hobbs: 2026 Society of Hematologic Oncology Meeting
-
Sep 13, 2026, 03:40Mizinga Moonze: When Blood Speaks – The Missing Link in Healthcare Sustainability
-
Sep 12, 2026, 17:55Dries De Wolf: Honored to Have Wolfgang Miesbach Comment on Our Latest Research
-
Sep 12, 2026, 17:53Usman Waheed: Introducing the Discovery of the 49th ISBT Blood Group System
-
Sep 12, 2026, 17:51Maria Sabater Lleal: Happy to Share Our Latest Work Exploring the Genetic Determinants of PE in VTE
-
Sep 12, 2026, 17:51Jeff Sternlicht: Why LDL-C and ApoB Remain King of the Hill?